title: [Adjuvant study of high-risk muscle invasive urothelial carcinoma : Open-label, multicenter, randomized phase III study with atezolizumab (anti-PD-L1 antibody) as adjuvant therapy compared with observation in patients with high-risk muscle invasive urothelial carcinoma after surgical resection (IMvigor010)- study AB 53/15 of the AUO].
authors.affiliation: AUO Geschäftsstelle, MeckEvidence, Seestr. 11, 17252, Schwarz, Deutschland. auo.presse@MeckEvidence.de.
authors.forename: H
authors.initials: H
authors.lastname: Rexer
authors.affiliation: Urologische Klinik und Poliklinik der Technischen Universität München, Klinikum rechts der Isar, München, Deutschland.
authors.forename: M
authors.initials: M
authors.lastname: Retz
authors.affiliation: Klinik für Urologie, Universitätsklinikum Düsseldorf, Düsseldorf, Deutschland.
authors.forename: P
authors.initials: P
authors.lastname: Albers
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage; D017024:Chemotherapy, Adjuvant / Q000379:methods; D015653:Cystectomy / Q000379:methods*; D018572:Disease-Free Survival; D005260:Female; D005858:Germany; D006801:Humans; D008297:Male; D008875:Middle Aged; D009130:Muscle, Smooth / Q000473:pathology; D009361:Neoplasm Invasiveness; D012307:Risk Factors; D015996:Survival Rate; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis / Q000473:pathology* / Q000628:therapy*; D057832:Watchful Waiting / Q000379:methods*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C000594389:atezolizumab